Skip to main content

Table 6 Comparisons between pre-therapy and 24-week post-therapy variables levels among CHC patients with SVRs

From: Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice

 

Therapy

Pre-therapy

24-week post-therapy

p values

(pre- vs. post-)

Adiponectin (μg/mL)

 

Total SVR patients

6.53 ± 2.77

5.45 ± 2.56

 < 0.001

 

Male SVR patients

5.85 ± 2.35

4.85 ± 2.42

 < 0.001

 

Female SVR patients

7.15 ± 2.98

5.98 ± 2.58

 < 0.001

HOMA-IR

 

Total SVR patients

3.25 ± 5.37

2.97 ± 3.09

0.417

 

Male SVR patients

3.92 ± 7.39

3.25 ± 3.70

0.491

 

Female SVR patients

2.62 ± 2.03

2.71 ± 2.37

0.327

 

Baseline IR (+

1.63 ± 0.51

1.99 ± 1.49

0.001

 

Baseline IR (−)

5.40 ± 7.69

4.29 ± 4.04

0.01

BMI

 

Total SVR patients

24.7 ± 3.9

24.9 ± 3.0

0.002

 

Male SVR patients

25.2 ± 3.4

25.5 ± 3.5

0.005

 

Female SVR patients

24.5 ± 4.38

24.4 ± 4.51

0.155

ALT

 

Total SVR patients

85.0 ± 94.8

23.5 ± 16.0

 < 0.001

 

Male SVR patients

100.7 ± 121.4

24.8 ± 15.0

 < 0.001

 

Female SVR patients

71.9 ± 60.4

21.0 ± 14.6

 < 0.001

eGFR

 

Total SVR patients

92.4 ± 38.5

87.4 ± 36.4

 < 0.001

 

Male SVR patients

94.8 ± 38.9

88.8 ± 35.8

 < 0.001

 

Female SVR patients

90.2 ± 38.7

85.8 ± 37.6

0.045

  1. CHC: chronic hepatitis C virus infection; SVR: sustained virological response; HOMA-IR: homeostatic model assessment for insulin resistance; BMI: body mass index; ALT: alanine transaminase; eGFR: estimated glomerular filtration rate